

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-36. (Canceled)

37. (Original) A composition for detecting a cancer cell in a biological sample of a patient, said composition comprising:

- (a) a first oligonucleotide; and
- (b) a second oligonucleotide;

wherein said first oligonucleotide and said second oligonucleotide hybridize to a first polynucleotide and to a second polynucleotide, respectively; wherein said first polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

38. (Original) The composition of claim 37 wherein said first polynucleotide and said second polynucleotide are complementary tissue-specific polynucleotides of the tissue-type of said cancer cell.

39. (Currently Amended) The composition of any one of claim 37 and claim 38 wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in ~~SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75, and SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:32, and SEQ ID NO:76.~~

40. (Currently Amended)The composition of any one of claim 37 and claim 38 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NO: 58 and 55-33-72.

41. (Original) A composition for detecting a cancer cell in a biological sample of a patient, said composition comprising:

- (a) a first oligonucleotide pair; and
- (b) a second oligonucleotide pair;

wherein said first oligonucleotide pair and said second oligonucleotide pair hybridize to a first polynucleotide (or complement thereof) and to a second polynucleotide (or complement thereof), respectively; wherein said first polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

42. (Original) The composition of claim 41 wherein said first polynucleotide and said second polynucleotide are complementary tissue-specific polynucleotides of the tissue-type of said cancer cell.

43. (Currently Amended) The composition of any one of claim 41 and claim 42 wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in ~~SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75 and, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:32, and SEQ ID NO:76.~~

44. (Currently Amended) The composition of any one of claim 41 and claim 42 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NOs: ~~33-72~~53, 54, 56, and 57.

45. (Currently Amended) A composition comprising an oligonucleotide primer or probe of between 15 and 100 nucleotides that comprises an oligonucleotide selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: ~~33-72~~53-58.

46. (Currently Amended) The composition of claim 45 comprising an oligonucleotide primer or probe selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: ~~33-72~~53-58.